GlassScriptPhysician profile
Blas Ledesma
NPI 1457748345
$1,834.92
in general payments reported to CMS, 2019-2025
19 companies · $904 in 2025
The $904 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $128 · 2022: $269 · 2023: $207 · 2024: $327 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,240 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.66 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $374.44 | 2021-2025 | Tecvayli, Darzalex, Rybrevant |
| Pfizer INC. | $299.01 | 2021-2025 | |
| Adaptive Biotechnologies Corporation | $186.48 | 2023-2025 | Clonoseq |
| Incyte Corporation | $169.26 | 2024-2025 | Jakafi |
| Alexion Pharmaceuticals, INC. | $139.25 | 2021-2025 | Ultomiris |
| Astellas Pharma US INC | $107.04 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $106.97 | 2022 | |
| Seagen INC. | $99.00 | 2025 | |
| Kite Pharma, INC. | $79.04 | 2025 | Yescarta |
| Abbvie INC. | $70.13 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $39.30 | 2025 | |
| Stemline Therapeutics INC. | $24.81 | 2025 | Elzonris |
| Glaxosmithkline, LLC. | $22.86 | 2024 | |
| Merck Sharp & Dohme LLC | $22.82 | 2025 | Prevymis |
| Morphosys, US INC. | $22.40 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $21.33 | 2023 | Venclexta |
| Astrazeneca Pharmaceuticals LP | $20.05 | 2025 | Lynparza |
| Genmab U.S., INC. | $19.53 | 2025 | Epkinly |
| Jazz Pharmaceuticals INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blas Ledesma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.